The AML Hub was pleased to speak with Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, Which AML patients benefit most from venetoclax treatment?
Daver begins by outlining the major impact made by venetoclax and its combinations in improving patient outcomes. He discusses age, comorbidities, and subtypes as factors to consider when selecting treatments. He highlights the similar response rates and lower toxicity of venetoclax compared to other therapies, such as intensive chemotherapy in NPM1-mutated AML. He goes on to explain instances where venetoclax yields superior outcomes and treatment scenarios for "middle-populations", based on individual patient profiles.